Shanghai – September 24, 2026 – Cooley advised Earendil Labs, an artificial intelligence-powered biotechnology company advancing next-generation biologics, on its research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology.

As part of the Agreement, Earendil Labs will receive a $55 million upfront payment, with the total potential value of the collaboration, including upfront, development, regulatory and sales milestone payments in excess of $1.5 billion. Earendil Labs is also eligible to receive tiered royalties on net product sales.

Lawyers Yiming Liu, Geoffrey Spolyar and Zack Gong led the Cooley team advising Earendil Labs, with support from Shawn Yu and Zhijing Yu.

Cooley previously advised Earendil Labs on its strategic collaboration with Sanofi in January 2026 and its exclusive license agreement with Sanofi in April 2025.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.